- Home
- PEN vs JAZZ Comparison
PEN vs JAZZ Comparison
Compare PEN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- JAZZ
- Stock Information
- Founded
- PEN 2004
- JAZZ 2003
- Country
- PEN United States
- JAZZ Ireland
- Employees
- PEN N/A
- JAZZ N/A
- Industry
- PEN Medical/Dental Instruments
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- JAZZ Health Care
- Exchange
- PEN Nasdaq
- JAZZ Nasdaq
- Market Cap
- PEN 7.0B
- JAZZ 6.5B
- IPO Year
- PEN 2015
- JAZZ 2007
- Fundamental
- Price
- PEN $238.85
- JAZZ $122.44
- Analyst Decision
- PEN Buy
- JAZZ Buy
- Analyst Count
- PEN 14
- JAZZ 14
- Target Price
- PEN $232.23
- JAZZ $174.14
- AVG Volume (30 Days)
- PEN 416.9K
- JAZZ 670.7K
- Earning Date
- PEN 10-30-2024
- JAZZ 11-06-2024
- Dividend Yield
- PEN N/A
- JAZZ N/A
- EPS Growth
- PEN N/A
- JAZZ 458.10
- EPS
- PEN 0.89
- JAZZ 7.04
- Revenue
- PEN $1,163,776,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- PEN $13.65
- JAZZ $7.43
- Revenue Next Year
- PEN $14.38
- JAZZ $6.39
- P/E Ratio
- PEN $267.31
- JAZZ $16.96
- Revenue Growth
- PEN 16.96
- JAZZ 5.23
- 52 Week Low
- PEN $148.00
- JAZZ $99.06
- 52 Week High
- PEN $277.34
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- PEN 62.72
- JAZZ 57.02
- Support Level
- PEN $234.62
- JAZZ $115.65
- Resistance Level
- PEN $242.95
- JAZZ $128.99
- Average True Range (ATR)
- PEN 6.23
- JAZZ 3.42
- MACD
- PEN -0.51
- JAZZ -0.18
- Stochastic Oscillator
- PEN 58.86
- JAZZ 59.78
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.